The Isoflavanoid (+)‐PTC Regulates Cell‐Cycle Progression and Mitotic Spindle Assembly in a Prostate Cancer Cell Line. Issue 5 (29th April 2022)

• Record Type: Journal Article
• Authors: Moraes de Farias, Kaio; Rosa‐Ribeiro, Rafaela; Souza, Edmarcia E.; Kobarg, Jörg; Banwell, Martin G.; de Brito Vieira Neto, José; Leyenne Alves Sales, Sarah; Roberto Ribeiro Costa, Paulo; Cavalcante dos Santos, Rafael; Vilaça Gaspar, Francisco; Gomes Barreto Junior, Amaro; da Conceição Ferreira Oliveira, Maria; Odorico de Moraes, Manoel; Libardi M. Furtado, Cristiana; Carvalho, Hernandes F.; Pessoa, Claudia
• Is Part Of: Chemistry & biodiversity. Volume 19:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-29
• Subjects: Pterocarpan -- PC-3 -- anticancer activity -- microtubule formation -- antimitotic drug; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Biodiversity -- Periodicals; 572
• DOI: 10.1002/cbdv.202200102
• Languages: English
• ISSNs: 1612-1872

Abstract

Abstract: Prostate cancer is the second most common malignancy in men and the development of effective therapeutic strategies remains challenging when more advanced, androgen‐independent or insensitive forms are involved. Accordingly, we have evaluated, using flow cytometry, confocal microscopy and image analysis, the anti‐proliferative effects of (+)‐2, 3, 9‐trimethoxypterocarpan [(+)‐PTC, 1 ] on relevant human prostate cancer cells as well as its capacity to control mitosis within them. In particular, the studies reported herein reveal that (+)‐PTC exerts anti‐proliferative activity against the PC‐3 cell lines by regulating cell‐cycle progression with mitosis being arrested in the prophase or prometaphase. Furthermore, it emerges that treatment of the target cells with this compound results in the formation of monopolar spindles, disorganized centrosomes and extensively disrupted γ‐tubulin distributions while centriole replication remains unaffected. Such effects suggest (+)‐PTC should be considered as a possible therapy for androgen‐insensitive/independent prostate cancer. Abstract :